Urothelial Cancer

Bernard H. Bochner, MD, FACS, discusses updates in the treatment of muscle-invasive bladder cancer and ongoing trials in the space.

Daniel P. Petrylak, MD, discusses the importance of molecularly-driven clinical trials and ongoing research with novel therapeutics in urothelial carcinoma.

Bernard H. Bochner, MD, FACS, highlights advancements in early-stage muscle-invasive bladder cancer and the necessity for multimodality approaches.

Daniel P. Petrylak, MD, discusses advancements in the treatment of patients with bladder cancer.

China’s NMPA accepted a sBLA for enfortumab vedotin plus pembrolizumab for the first-line treatment of locally advanced or metastatic urothelial cancer.

Experts delineate the latest developments and lingering questions in bladder and renal cancers, covering pivotal trials, emerging therapies, and optimal management approaches.

Jason Efstathiou, MD, discusses the status of bladder preservation therapy for muscle-invasive bladder cancer.

Elisabeth I. Heath, MD, FACP, discusses what makes NECTIN-4 an attractive target in drug development and the significance of the EV-302/KEYNOTE-A39 trial findings.

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

The FDA has approved nivolumab plus cisplatin and gemcitabine for first-line use in adult patients with unresectable or metastatic urothelial carcinoma.

Patients with upper tract urothelial cancer who received adjuvant chemotherapy after nephroureterectomy experienced extended DFS vs those who received surveillance.

Frontline maintenance therapy with avelumab following platinum-based chemotherapy led to similar outcomes in routine clinical practice and the JAVELIN Bladder 100 trial in metastatic urothelial cancer.

Nikhil A. Gopal, MD, discusses how the phase 3 EV-302 and CheckMate 901 trials have advanced the treatment paradigm in metastatic urothelial cancer.

Robert Huddart, PhD, discusses the FDA approval of erdafitinib for patients with FGFR3-altered metastatic urothelial carcinoma.

Chandler H. Park, MD, FACP, discusses the rationale for evaluating sacituzumab govitecan plus pembrolizumab in metastatic urothelial carcinoma.

Anthony T. Nguyen, MD, PhD, discusses the role of concurrent chemotherapy with trimodal therapy in patients with muscle-invasive bladder cancer.

Chandler H. Park, MD, FACP, discusses the use of sacituzumab govitecan plus pembrolizumab in patients with metastatic urothelial carcinoma.

Abhishek Tripathi, MD, discusses the phase 1/2 NEMIO trial of durvalumab/chemotherapy with/without tremelimumab in muscle-invasive bladder cancer.

The sNDA for enfortumab vedotin-ejfv plus pembrolizumab in patients with metastatic urothelial cancer has received priority review in Japan.

Anthony T. Nguyen, MD, PhD, discusses the methodology of trimodal therapy in patients with muscle-invasive bladder cancer.

Matthew Galsky, MD, discusses the significance of the FDA approval of enfortumab vedotin plus pembrolizumab as a first-line regimen in urothelial cancer.

Abhishek Tripathi, MD, discusses the significance of data from the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma.

Matthew Galsky, MD, discusses the FDA approval of enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

Petros Grivas, MD, PhD, discusses 2023 updates regarding the treatment of patients with metastatic/unresectable urothelial carcinoma.

A sNDA seeking approval of enfortumab vedotin plus pembrolizumab for first-line use in patients with urothelial cancer has been submitted to Japan’s MHLW.

Dr. Sonpavde discusses the efficacy and safety findings from this randomized, open-label trial enrolling patients with advanced or metastatic urothelial carcinoma who had not received prior systemic chemotherapy.

The type II variation application for enfortumab vedotin plus pembrolizumab in untreated metastatic urothelial cancer has been validated by the EMA.

Adjuvant pembrolizumab generated a disease-free survival benefit vs observation in patients with muscle-invasive and locally advanced urothelial carcinoma.

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

Pembrolizumab plus cabozantinib was efficacious in the first-line treatment of patients with cisplatin-ineligible urothelial carcinoma.